Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779687 | 0.73 | KDM1A (0.38) | KDM1ASIGMAR1EBPMAPK1SMN1; SMN2 | |
| SCHEMBL4133169 | 0.72 | CYP3A4 (0.58) | KDM1ASIGMAR1PGRKDM5AKDM4C | |
| SCHEMBL6316631 | 0.71 | PGR (0.47) | KDM1ASIGMAR1MAPK1PGRADORA3 | |
| SCHEMBL779503 | 0.69 | ADRA2A (0.46) | KDM1AKDM5AKDM4CKDM5BADORA3 | |
| SCHEMBL768782 | 0.67 | AKR1B1 (0.40) | KDM1ASIGMAR1EBPADORA3 | |
| SCHEMBL9906167 | 0.66 | KDM1A (0.49) | KDM1ASIGMAR1PGRADORA3 | |
| SCHEMBL7321561 | 0.66 | SIGMAR1 (0.51) | KDM1ASIGMAR1 | |
| SCHEMBL6689565 | 0.66 | KDM1A (0.56) | KDM1ASIGMAR1EBPMAPK1SMN1; SMN2 | |
| SCHEMBL29617949 | 0.66 | KDM1A (0.56) | KDM1ASIGMAR1EBPMAPK1SMN1; SMN2 | |
| SCHEMBL4195493 | 0.65 | KDM1A (0.50) | KDM1ASIGMAR1MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | KDM1A 2917/4885SIGMAR1 1863/4885EBP 655/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | KDM1A 2936/4885SIGMAR1 1958/4885EBP 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.